Harvard U Med School IRB #1
Welcome,         Profile    Billing    Logout  
 4 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hobbs, Gabriela
NCT04644211: Ruxolitinib in Thrombocythemia and Polycythemia Vera

Recruiting
2
60
US
Ruxolitinib, Jakafi
Massachusetts General Hospital, Incyte Corporation
Essential Thrombocythemia, Polycythemia Vera
12/24
12/24
NCT03427866: Ruxolitinib Pre-, During- and Post-HSCT for Patients with Primary or Secondary Myelofibrosis.

Active, not recruiting
2
44
US
Ruxolitinib, Jakafi
Massachusetts General Hospital, Incyte Corporation
Myelofibrosis
05/24
05/25
PXS5505-MF-101, NCT04676529: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Active, not recruiting
1/2
43
US, RoW
PXS-5505
Syntara, Parexel
Myelofibrosis
08/25
08/25
NCT03042689: Study of Regorafenib in Patients With Advanced Myeloid Malignancies

Completed
1
16
US
Regorafenib, Stivarga
Massachusetts General Hospital, Bayer
Acute Myeloid Leukemia
09/21
02/23
NCT06343805: A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Recruiting
1
76
US
AJ1-11095
Ajax Therapeutics, Inc.
Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, PMF, PPV-MF, PET-MF
10/26
02/27
NCT05842603: I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

Recruiting
N/A
30
US
Cardiac Lifestyle Program
Massachusetts General Hospital
Myeloproliferative Disorders, Leukemia
01/25
01/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hobbs, Gabriela
NCT04644211: Ruxolitinib in Thrombocythemia and Polycythemia Vera

Recruiting
2
60
US
Ruxolitinib, Jakafi
Massachusetts General Hospital, Incyte Corporation
Essential Thrombocythemia, Polycythemia Vera
12/24
12/24
NCT03427866: Ruxolitinib Pre-, During- and Post-HSCT for Patients with Primary or Secondary Myelofibrosis.

Active, not recruiting
2
44
US
Ruxolitinib, Jakafi
Massachusetts General Hospital, Incyte Corporation
Myelofibrosis
05/24
05/25
PXS5505-MF-101, NCT04676529: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Active, not recruiting
1/2
43
US, RoW
PXS-5505
Syntara, Parexel
Myelofibrosis
08/25
08/25
NCT03042689: Study of Regorafenib in Patients With Advanced Myeloid Malignancies

Completed
1
16
US
Regorafenib, Stivarga
Massachusetts General Hospital, Bayer
Acute Myeloid Leukemia
09/21
02/23
NCT06343805: A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Recruiting
1
76
US
AJ1-11095
Ajax Therapeutics, Inc.
Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, PMF, PPV-MF, PET-MF
10/26
02/27
NCT05842603: I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

Recruiting
N/A
30
US
Cardiac Lifestyle Program
Massachusetts General Hospital
Myeloproliferative Disorders, Leukemia
01/25
01/25

Download Options